EVALUATION OF ANTIDIABETIC POTENTIAL OF BROMOCRIPTINE AND PANDANUS EXTRACTS IN STREPTOZOTOCIN-INDUCED DIABETIC RATS WITH HISTOPATHOLOGICAL EVALUATION OF PANCREATIC TISSUE
Main Article Content
Keywords
Pandanus amaryllifolius, Bromocriptine, antidiabetic, pancreatic amylase, pancreatic lipase
Abstract
ABSTRACT:
Background: Diabetes is a highly heritable disease worldwide, causing significant damage to vital organs and leading to decreased production of pancreatic enzymes, including amylase and lipase Objectives: Pandanus amaryllifolius Roxb (pandan) has been found to enhance insulin sensitivity, reduce insulin resistance, and exhibit potential in treating type 2 diabetes mellitus. This study investigates the antidiabetic properties of pandan, both alone and in combination with Bromocriptine, to produce a synergistic effect in rat models of induced diabetes Study Design: Experimental. Setting: Karachi University.
Methods: The in-vivo testing was done by taking the blood samples of normal and diabetic male rats. Diabetes was induced by streptozotocin and blood glucose level, pancreatic amylase and lipase were assessed.
Results: In this, pandanus as well as Bromocriptine was found to improve blood glucose level and significantly enhance pancreatic amylase and lipase levels compared to control diabetic group. Moreover, diabetic induced group caused substantial damage to pancreatic architecture, which was notably reversed by pandanus and Bromocriptine. In conclusion, Pandanus demonstrates potential in treating diabetes and protecting the pancreas from diabetes-induced damage Conclusion: The studied concluded that pandanus have marked antidiabetic activity and protecting the pancreas from damage.
References
2. Honeycutt AA, Boyle JP, Broglio KR, Thompson TJ, Hoerger TJ, Geiss LS, et al. A dynamic Markov model for forecasting diabetes prevalence in the United States through 2050. Health Care Manag Sci. 2003;6:155–64.
3. Rathmann W, Giani G. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:2568–9.
4. Chiabchalard A, Nooron N . Antihyperglycemic effects of Pandanus amaryllifolius Roxb. leaf extract. Pharmacogn Mag. 2015 Jan-Mar;11(41):117–122.
5. Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care. 2003; 26:1277–94.
6. Peungvicha P, Thirawarapan SS, Watanabe H. Possible mechanism of hypoglycemic effect of 4- hydroxybenzoic acid, a constituent of Pandanus odorus root. Jpn J Pharmacol. 1998;78:395–8.
7. Peungvicha P, Temsiririrkkul R, Prasain JK, Tezuka Y, Kadota S, Thirawarapan SS, et al. 4- Hydroxybenzoic acid: A hypoglycemic constituent of aqueous extract of Pandanus odorus root. J Ethnopharmacol. 1998;62:79–84.
8. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes". J Pharmacol Exp Ther. 303 (2): 791–804.
9. Ghasemzadeh A, Jaafar H.Z.E. Optimization of reflux conditions for total flavonoid and total phenolic extraction and enhanced antioxidant capacity in Pandan (Pandanus amaryllifolius Roxb.) using response surface methodology (2014), p. 523120
10. A. Chiabchalard, N. Nooron .Antihyperglycemic effects of Pandanus amaryllifolius Roxb. leaf extract. (2015), pp. 117-122
11. Bothon FTD, Debiton E, Avlessi F, Forestler C, Teulade JC, Sohounhloue DKC. In vitro biological effects of two anti-diabetic medicinal plants used in Benin as folk medicine. BMC Complement Altern Med 2013; 13:51.
12. Ogundajo A, Ashafa AT. Phytochemical Compositions and In vitro Assessments of Antioxidant and Antidiabetic Potentials of Fractions from Ehretia cymosa Thonn. Pharmacogn Mag 2017; 13.
13. Olennikov DN, Chirikova NK, Kashchenko NI, Nikolaev VM, Kim SW, Vennos C. Bioactive Phenolics of the Genus Artemisia (Asteraceae): HPLC-DAD-ESI-TQ-MS/MS Profile of the Siberian Species and Their Inhibitory Potential Against α-Amylase and α-Glucosidase. Front Pharmacol 2018; 9:756
14. Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor". J Pharmacol Exp Ther. 303 (2): 805–14.
15. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, et al. (June 2010). "The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells". Biochemical Pharmacology. 79 (12): 1827–36.
16. Luo S, Luo J, Cincotta AH: Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hamster. Chronobiol Int. 2000, 17 (2): 155-172..
17. Luo S, Meier AH, Cincotta AH: Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology. 1998, 68 (1): 1-10.
18. Bina KG, Cincotta AH: Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology. 2000, 71 (1): 68-78.
19. Hansen B, Shaffrir E, Cincotta AH. Hypothalamic role in the insulin resistance syndrome. In Insulin Resistance Syndrome. Hansen B, Shaffrir E, Eds. London, Taylor and Francis, 2002, p. 271–312
20. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total cholesterol. Clinical Chemistry. 1974; 20(4): 470-475.
21. Cloete L. Diabetes mellitus: an overview of the types, symptoms, complications and management: Nurs Stand. 2022 Jan 5;37(1):61-66.
22. Fletcher B, Gulanick M, Lamendola C. Risk factors for type 2 diabetes mellitus: J Cardiovasc Nurs. 2002 Jan;16(2):17-23
23. Flórez H. Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations: Invest Clin. 1997 Mar;38(1):39-52
24. Florez H, Valbuena H, Ryder E, Rincón E, Campos G, Castillo S, González J, Fernández V, Raleigh X. Dyslipidemia and hyperinsulinemia in normoglycemic-obese relatives of patients with non-insulin dependent diabetes mellitus : Invest Clin. 1995 Sep;36(3):131-47.
25. Reaven G M. Pathophysiology of insulin resistance in human disease: Physiol Re. 1995 Jul;75(3):473-86.
26. Cincotta AH, Meier AH, Cincotta Jr M: Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999, 8 (10): 1683-1707.
27. Luo S, Liang Y, Cincotta AH. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters: Neuroendocrinolog.1999 Mar;69(3):160-6.
28. Lopez Vicchi F, Luque GM, Brie B, Nogueira JP, Garcia Tornadu I, Becu-Villalobos D. Dopaminergic drugs in type 2 diabetes and glucose homeostasis: Pharmacol Res. 2016 Jul:109:74-80.
29. Framnes-DeBoer SN, Bakke E, Yalamanchili S, Peterson H, Sandoval DA, Seeley RJ, Arble DM. Bromocriptine improves glucose tolerance independent of circadian timing, prolactin, or the melanocortin-4 receptor :Am J Physiol Endocrinol Metab.2020 Jan 1;318(1):E62-E71.
30. Sasidharan S, Sumathi V, Jegathambigai NR, Latha LY. Antihyperglycaemic effects of ethanol extracts of Carica papaya and Pandanus amaryfollius leaf in streptozotocin-induced diabetic mice: at Prod Res. 2011 Dec;25(20):1982-7
31. Peungvicha P, Thirawarapan SS, Watanabe H. Hypoglycemic effect of water extract of the root of Pandanus odorus RIDL: Biol Pharm Bull. 1996 Mar;19(3):364-6.
32. Peungvicha P, Temsiririrkkul R, Prasain JK, Tezuka Y, Kadota S, Thirawarapan SS, Watanabe H. 4-Hydroxybenzoic acid: a hypoglycemic constituent of aqueous extract of Pandanus odorus root: J Ethnopharmacol.1998 Aug;62(1):79-84.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Sonia Khan
Department of Pharmacology, Faculty of Pharmacy, Al-Tibri Medical College, Karachi & Faculty of Pharmacy, University of Karachi
Syeda Afroz
Associate Professor, Department of Pharmacology, Faculty of Pharmacy, University of Karachi
Noor Jahan
Professor, Department of Pharmacology, Dow University of Health Sciences
Saira Bugti
Professor, Department of Pathology, Fazaiya RUrduuth Pfau Medical College, Air University Karachi.
Mehjabeen
Professor, Department of Pharmacology, Faculty of Pharmacy, Federal University of Arts, Science and Technology.
Muhammad Tariq Khan
Assistant Professor, Department of Pharmacology, Faculty of Pharmacy, Federal Urdu University of Arts, Science and Technology.
Saima Mahmood Malhi
Associate Professor, Department of Pharmacology, Dow University of Health Sciences.
Azmat Ara
Lecturer, Department of Pharmaceutics, University of Karachi.